Summer Sale

Up to 30% off — ends 7 Aug

ONLY00h00m00s

Get 30% Off

Up to 30% off — ends 7 Aug

ONLY00h00m00s

Davide Poli

Istituto di Ricerche Farmacologiche Mario Negri

Italy

This profile is automatically generated from trusted academic sources.

Google Scholar

ORCID

How do I reach out?

Meet Kite AI

Contact this professor

ORCID

Google Scholar

Research Interests

Pharmacotherapy

20%

Pharmacology

10%

Oncology

20%

Adjuvant Therapy

20%

Therapeutic Target

10%

Chemoprevention

10%

Retinal Disease

10%

Ask ApplyKite AI

Start chatting

How can you help me contact this professor?

What are this professor's research interests?

How should I write an email to this professor?

Articles3

Randomized phase II trial of weekly paclitaxel vs. cediranib-olaparib (continuous or intermittent schedule) in platinum-resistant high-grade epithelial ovarian cancer

Article Link

Year:

2022

Oxaliplatin plus fluoropyrimidines as adjuvant therapy for colon cancer in older patients: A subgroup analysis from the TOSCA trial

Article Link

Year:

2021

Author Correction: Visual field loss and vision-related quality of life in the Italian Primary Open Angle Glaucoma Study (Scientific Reports, (2018), 8, 1, (619), 10.1038/s41598-017-19113-z)

Article Link

Year:

2020

Collaborators2

gianluca manni

full professor

University of Rome Tor Vergata

ITALY

Francesca Tettamanzi

Humanitas University

ITALY

How do I reach out?

Meet Kite AI